Table 2.
miRNAs having the most miRNA target sites in severe acute respiratory coronavirus 2 RNA
| miRNA | Abundance in HBE | MTS |
Potential Impact on Cellular Processes | ||||||
|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 | SARS | MERS | NL63 | OC43 | 229E | HKU1 | |||
| hsa-miR-449c-5p | Q2/Q3 | 9 | 5 | 3 | 2 | 1 | 3 | 2 | Targets c-Myc and inhibits NSCLC cell progression (68) |
| hsa-miR-3940–5p | Q1/nd. | 9 | 11 | 5 | 7 | 2 | 3 | 3 | Tumor Suppressor in NSCLCs (87) |
| hsa-miR-34c -5p | Q3/Q3 | 9 | 5 | 11 | 1 | 6 | 7 | 3 | UPR-dependent and targets XBP1 (4, 6). |
| hsa-miR-34a -5p | Q3/Q3 | 9 | 8 | 11 | 0 | 4 | 6 | 5 | UPR-IRE1 dependent and targets Caspase 2 (60). |
| hsa-miR-149-3p | Q2/Q2 | 8 | 4 | 6 | 2 | 4 | 1 | 2 | Deregulated in COPD (32). Suppresses hepatic inflammatory response through antagonizing the STAT3 signaling pathway (126). |
| hsa-miR-92a-1-5p | Q3/Q2 | 8 | 4 | 4 | 5 | 5 | 2 | 0 | Unknown |
| hsa-miR-138-5p | Q3/Q3 | 8 | 6 | 4 | 0 | 4 | 2 | 1 | Deregulated in colorectal and lung cancers (42, 127). |
| hsa-miR-4433b-3p | Q1/nd | 8 | 6 | 13 | 7 | 5 | 3 | 5 | Unknown |
| hsa-miR-766-5p | Q3/Q1 | 7 | 4 | 3 | 1 | 5 | 4 | 3 | Unknown |
| hsa-miR-6741-5p | Q1/Q1 | 7 | 6 | 9 | 3 | 9 | 7 | 3 | Unknown |
Abundance in human bronchial epithelial cells is provided as a quartile (Q) of raw next generation sequencing reads distribution for 16HBE14o-/primary HBE. HBE, human bronchial epithelial; IRE, inositol-requiring enzyme; nd, not detected; NSCLC, non-small cell lung cancer; UPR, unfolded protein response.